Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 1/20 | 0.46 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.46 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CTSG | P08311 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.38 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.38 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10027286 | 0.88 | DCTPP1 (0.42) | ADORA3ADORA2AELANECTSGDCTPP1 | |
| SCHEMBL10027285 | 0.79 | GCGR (0.37) | ADORA3ADORA2ANPC1ALDH1A1RAB9A | |
| SCHEMBL10027235 | 0.75 | MAPT (0.36) | ELANECTSGKDM4EALDH1A1MAPT | |
| SCHEMBL17808760 | 0.73 | LMNA (0.36) | GRIN1GRIN2BALDH1A1MAPTHPGD | |
| SCHEMBL17808764 | 0.73 | PDE3B (0.36) | ELANECTSGKDM4EFYNCOMT | |
| SCHEMBL10027234 | 0.72 | MAPT (0.43) | ELANECTSGKDM4EALDH1A1MAPT | |
| SCHEMBL17808740 | 0.72 | USP7 (0.36) | KDM4ENPC1ALDH1A1MAPTHPGD | |
| SCHEMBL17808792 | 0.72 | CHEK1 (0.49) | ELANECTSGKDM4EALDH1A1MAPT | |
| SCHEMBL14161893 | 0.70 | FLT3 (0.53) | CNR1CNR2DCTPP1KDM4ENPC1 | |
| SCHEMBL19361118 | 0.69 | AURKA (0.36) | MAPTFYNKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-8163760-B2 | Use of pyridopyrimidine compounds in the treatment of gliomas | PRANA BIOTECHNOLOGY LIMITED (AU) | 2012-04-24 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | PRANA BIOTECHNOLOGY LIMITED (AU) | 2010-03-18 | — | — | US | disclosed |
| WO-2007147217-A1 | METHOD OF TREATMENT OF GLIOMA BRAIN TUMOUR | PRANA BIOTECHNOLOGY LIMITED (AU) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069393-A1 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME | MGMT, DHFR, IDH2 | SMARCA2 2676/4885SMARCA4 3050/4885BRD9 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.